INCYTE CORPORATION (INCY) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-03-31..
Quick ratio
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Current obligations | 1.49B USD | Liabilities, Current |
| Cash and equivalents | 3.46B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | 115.62M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | $1.49B | $3.46B | (m) | (m) | $115.62M | (m) |
| 2025-12-31 | (m) | $1.52B | $3.10B | (m) | (m) | $101.06M | (m) |
| 2025-09-30 | (m) | $1.34B | $2.46B | (m) | (m) | $83.45M | (m) |
| 2025-06-30 | (m) | $1.28B | $1.95B | (m) | (m) | $83.42M | (m) |
| 2025-03-31 | (m) | $1.72B | $1.94B | (m) | (m) | $63.98M | (m) |
| 2024-12-31 | (m) | $1.64B | $1.69B | (m) | (m) | $58.87M | (m) |
| 2024-09-30 | (m) | $1.50B | $1.30B | $467.24M | (m) | $70.44M | (m) |
| 2024-06-30 | (m) | $1.34B | $987.29M | $462.21M | (m) | $100.70M | (m) |
| 2024-03-31 | (m) | $1.40B | $3.35B | $504.48M | (m) | $63.64M | (m) |
| 2023-12-31 | (m) | $1.24B | $3.21B | $442.67M | (m) | $62.97M | (m) |
| 2023-09-30 | (m) | $1.12B | $3.23B | $289.22M | (m) | $57.20M | (m) |
| 2023-06-30 | (m) | $1.12B | $3.13B | $292.24M | (m) | $35.94M | (m) |
| 2023-03-31 | (m) | $1.01B | $2.82B | $291.66M | (m) | $40.88M | (m) |
| 2022-12-31 | (m) | $1.16B | $2.95B | $287.54M | (m) | $41.99M | (m) |
| 2022-09-30 | (m) | $1.01B | $2.69B | $286.50M | (m) | $45.87M | (m) |
| 2022-06-30 | (m) | $926.67M | $2.44B | $287.04M | (m) | $54.50M | (m) |
| 2022-03-31 | (m) | $886.16M | $2.26B | $287.40M | (m) | $35.46M | (m) |
| 2021-12-31 | (m) | $854.31M | $2.06B | $290.75M | (m) | $27.90M | (m) |
| 2021-09-30 | (m) | $742.71M | $2.00B | $285.05M | (m) | $21.30M | (m) |
| 2021-06-30 | (m) | $660.32M | $1.80B | $283.38M | (m) | $16.68M | (m) |
| 2021-03-31 | (m) | $623.88M | $1.67B | $292.43M | (m) | $16.70M | (m) |
| 2020-12-31 | (m) | $631.20M | $1.51B | $288.37M | (m) | $16.43M | (m) |
| 2020-09-30 | (m) | $606.20M | $1.50B | $237.03M | (m) | $17.01M | (m) |
| 2020-06-30 | (m) | $556.51M | $1.33B | $262.76M | (m) | $16.34M | (m) |
| 2020-03-31 | (m) | $503.41M | $1.04B | $259.35M | (m) | $13.98M | (m) |
| 2019-12-31 | (m) | $513.34M | $1.83B | $284.87M | (m) | $11.40M | (m) |
| 2019-09-30 | (m) | $461.68M | $1.70B | $284.19M | (m) | $7.37M | (m) |
| 2019-06-30 | (m) | $367.11M | $1.42B | $279.63M | (m) | $6.53M | (m) |
| 2019-03-31 | (m) | $364.51M | $1.30B | $281.32M | (m) | $7.13M | (m) |
| 2018-12-31 | (m) | $425.28M | $1.16B | $274.34M | (m) | $6.97M | (m) |
| 2018-09-30 | (m) | $422.49M | $1.11B | $263.13M | (m) | $5.99M | (m) |
| 2018-06-30 | (m) | $368.24M | $928.52M | $269.87M | (m) | $5.87M | (m) |
| 2018-03-31 | (m) | $381.07M | $894.43M | $276.63M | (m) | $4.63M | (m) |
| 2017-12-31 | (m) | $375.40M | $899.51M | $270.14M | (m) | $6.48M | (m) |
| 2017-09-30 | (m) | $319.94M | $1.13B | $153.34M | (m) | $3.26M | (m) |
| 2017-06-30 | (m) | $293.16M | $451.75M | $156.85M | (m) | $2.93M | (m) |
| 2017-03-31 | (m) | $304.72M | $361.82M | $150.13M | (m) | $3.96M | (m) |
| 2016-12-31 | (m) | $273.50M | $652.34M | $156.20M | (m) | $4.11M | (m) |
| 2016-09-30 | (m) | $240.54M | $580.10M | $136.49M | (m) | $4.08M | (m) |
| 2016-06-30 | (m) | $198.99M | $487.65M | $141.54M | (m) | $6.12M | (m) |
| 2016-03-31 | (m) | $200.32M | $657.62M | $153.05M | (m) | $1.31M | (m) |
| 2015-12-31 | (m) | $168.01M | $521.44M | $186.34M | (m) | $1.78M | (m) |
| 2015-09-30 | (m) | $155.82M | $445.80M | $189.24M | (m) | $2.43M | (m) |
| 2015-06-30 | (m) | $192.47M | $439.68M | $187.79M | (m) | $1.90M | (m) |
| 2015-03-31 | (m) | $225.59M | $421.82M | $163.60M | (m) | $2.41M | (m) |
| 2014-12-31 | (m) | $221.51M | $452.30M | $147.97M | (m) | $358.00K | (m) |
| 2014-09-30 | (m) | $124.66M | $382.00M | $150.35M | (m) | $402.00K | (m) |
| 2014-06-30 | (m) | $112.55M | $406.26M | $102.49M | (m) | $269.00K | (m) |
| 2014-03-31 | (m) | $106.94M | $436.58M | $82.65M | (m) | $347.00K | (m) |
| 2013-12-31 | (m) | $108.04M | $471.43M | $37.58M | (m) | $406.00K | (m) |
| 2013-09-30 | (m) | $109.50M | $272.12M | $19.05M | (m) | $359.00K | (m) |
| 2013-06-30 | (m) | $102.96M | $258.20M | $19.25M | (m) | $133.00K | (m) |
| 2013-03-31 | (m) | $121.28M | $265.81M | $4.37M | (m) | $189.00K | (m) |
| 2012-12-31 | (m) | $136.07M | $224.06M | $4.36M | (m) | $278.00K | (m) |
| 2012-09-30 | (m) | $137.64M | $239.08M | $4.52M | (m) | $190.00K | (m) |
| 2012-06-30 | (m) | $139.73M | $257.56M | $4.24M | (m) | $188.00K | (m) |
| 2012-03-31 | (m) | $142.30M | $231.85M | $4.56M | (m) | (m) | (m) |
| 2011-12-31 | (m) | $135.61M | $273.16M | $4.43M | (m) | (m) | (m) |
| 2011-09-30 | (m) | $120.96M | $312.33M | $4.65M | (m) | (m) | (m) |
| 2011-06-30 | (m) | $110.67M | $359.07M | $5.04M | (m) | (m) | (m) |
| 2011-03-31 | (m) | $110.18M | $377.84M | $5.78M | (m) | (m) | (m) |
| 2010-12-31 | (m) | $113.57M | $417.91M | $6.26M | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $388.80M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $414.09M | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | $404.75M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $449.82M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $178.77M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |